Emerging therapeutic uses of direct-acting oral anticoagulants: An evidence-based perspective

Pharmacological Research

Volumn 120, Issue , 2017, Pages 206-218

  Raschi, Emanuel ^a   Bianchin, Matteo ^a   De Ponti, Roberto ^b   De Ponti, Fabrizio ^a   Ageno, Walter ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cancer; Cirrhosis; Direct acting anticoagulants; Evidence based medicine; Heparin induced thrombocytopenia; Non vitamin K anticoagulants; Systematic review

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CANCER PATIENT; CASE STUDY; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; END STAGE RENAL DISEASE; EVIDENCE BASED MEDICINE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVER CIRRHOSIS; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SICKLE CELL ANEMIA; SYSTEMATIC REVIEW (TOPIC); UNCERTAINTY; VENOUS THROMBOEMBOLISM; ANIMAL; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; EVIDENCE BASED PRACTICE; NEOPLASM; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; EVIDENCE-BASED PRACTICE; HEMORRHAGE; HUMANS; NEOPLASMS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 85017270149     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2017.03.026     Document Type: Review

References (104)

1. [1] Wells, P.S., Forgie, M.A., Rodger, M.A., Treatment of venous thromboembolism. JAMA 311 (2014), 717–728.
2. [2] Steinberg, B.A., Piccini, J.P., Anticoagulation in atrial fibrillation. BMJ, 348, 2014, g2116.
3. [3] Lip, G.Y., Lane, D.A., Stroke prevention in atrial fibrillation: a systematic review. JAMA 313 (2015), 1950–1962.
4. [4] Verheugt, F.W., Granger, C.B., Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386 (2015), 303–310.
5. [5] Raschi, E., Bianchin, M., Ageno, W., De Ponti, R., De Ponti, F., Risk-Benefit profile of direct-Acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf. 39 (2016), 1175–1187.
6. [6] Li, G., Holbrook, A., Jin, Y., Zhang, Y., Levine, M.A., Mbuagbaw, L., Witt, D.M., Crowther, M., Connolly, S., Chai-Adisaksopha, C., Wan, Z., Cheng, J., Thabane, L., Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin between observational studies using propensity score methods and randomized controlled trials. Eur. J. Epidemiol. 31 (2016), 541–561.
7. [7] Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A.S., Oldgren, J., Popescu, B.A., Schotten, U., Van, P.B., Vardas, P., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESCEndorsed by the European Stroke Organisation (ESO). Eur. Heart J., 2016, 2016.
8. [8] You, J.J., Singer, D.E., Howard, P.A., Lane, D.A., Eckman, M.H., Fang, M.C., Hylek, E.M., Schulman, S., Go, A.S., Hughes, M., Spencer, F.A., Manning, W.J., Halperin, J.L., Lip, G.Y., 9th ed. Antithrombotic Therapy for Atrial Fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 141, 2012, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, e531S–e575S (Chest).
9. [9] Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C.S., Morris, T.A., Sood, N., Stevens, S.M., Vintch, J.R., Wells, P., Woller, S.C., Moores, L., Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149 (2016), 315–352.
10. [10] Kovacs, R.J., Flaker, G.C., Saxonhouse, S.J., Doherty, J.U., Birtcher, K.K., Cuker, A., Davidson, B.L., Giugliano, R.P., Granger, C.B., Jaffer, A.K., Mehta, B.H., Nutescu, E., Williams, K.A., Practical management of anticoagulation in patients with atrial fibrillation. J. Am. Coll. Cardiol. 65 (2015), 1340–1360.
11. [11] Shields, A.M., Lip, G.Y., Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. J. Intern. Med. 278 (2015), 1–18.
12. [12] Lip, G.Y., Potpara, T., Boriani, G., Blomstrom-Lundqvist, C., A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. J. Intern. Med. 279 (2016), 467–476.
13. [13] Van G, I., Hobbelt, A.H., Marcos, E.G., Schotten, U., Cappato, R., Lewalter, T., Schwieler, J., Rienstra, M., Boriani, G., Tailored treatment strategies: a new approach for modern management of atrial fibrillation. J. Intern. Med. 279 (2016), 457–466.
14. [14] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A.J., Kirchhof, P., Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
15. [15] Lip, G.Y., Lane, D.A., Matching the NOAC to the patient: remember the modifiable bleeding risk factors. J. Am. Coll. Cardiol. 66 (2015), 2282–2284.
16. [16] Raschi, E., Bianchin, M., Ageno, W., De Ponti, R., De Ponti, F., Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications. Pol. Arch. Med. Wewn 126:7–8 (2016), 552–561.
17. [17] Chan, N.C., Eikelboom, J.W., Weitz, J.I., Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ. Res. 118 (2016), 1409–1424.
18. [18] Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., Ezekowitz, M.D., Granger, C.B., Halperin, J.L., Hohnloser, S.H., Hylek, E.M., Kirchhof, P., Lane, D.A., Verheugt, F.W., Veltkamp, R., Lip, G.Y., Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur. Heart J.(February (4)), 2016, 10.1093/eurheartj/ehv643 (Epub ahead of print).
19. [19] Diener, H.C., Aisenberg, J., Ansell, J., Atar, D., Breithardt, G., Eikelboom, J., Ezekowitz, M.D., Granger, C.B., Halperin, J.L., Hohnloser, S.H., Hylek, E.M., Kirchhof, P., Lane, D.A., Verheugt, F.W., Veltkamp, R., Lip, G.Y., Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur. Heart J.(February (4)), 2016, 10.1093/eurheartj/ehw069 (Epubaheadofprint).
20. [20] Bertoletti, L., Ollier, E., Duvillard, C., Delavenne, X., Beyens, M.N., De, M.E., Bellet, F., Basset, T., Mismetti, P., Laporte, S., Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol. Res. 118 (2017), 33–42.
21. [21] Salvo, F., Bezin, J., Bosco-Levy, P., Letinier, L., Blin, P., Pariente, A., Moore, N., Pharmacological treatments of cardiovascular diseases: evidence from real-life studies. Pharmacol. Res. 118 (2017), 43–52.
22. [22] Shea, B.J., Grimshaw, J.M., Wells, G.A., Boers, M., Andersson, N., Hamel, C., Porter, A.C., Tugwell, P., Moher, D., Bouter, L.M., Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med. Res. Methodol., 7, 2007, 10.
23. [23] Sardar, P., Chatterjee, S., Chaudhari, S., Lip, G.Y., New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J. Am. Geriatr. Soc. 62 (2014), 857–864.
24. [24] Sharma, M., Cornelius, V.R., Patel, J.P., Davies, J.G., Molokhia, M., Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation 132 (2015), 194–204.
25. [25] Sadlon, A.H., Tsakiris, D.A., Direct oral anticoagulants in the elderly: systematic review and meta-analysis of evidence, current and future directions. Swiss Med. Wkly, 146, 2016, w14356.
26. [26] Abraham, N.S., Singh, S., Alexander, G.C., Heien, H., Haas, L.R., Crown, W., Shah, N.D., Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ, 350, 2015, h1857.
27. [27] vgil-Tsadok, M., Jackevicius, C.A., Essebag, V., Eisenberg, M.J., Rahme, E., Behlouli, H., Pilote, L., Dabigatran use in elderly patients with atrial fibrillation. Thromb. Haemost. 115 (2016), 152–160.
28. [28] Romanelli, R.J., Nolting, L., Dolginsky, M., Kym, E., Orrico, K.B., Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis. Circ. Cardiovasc. Qual. Outcomes 9 (2016), 126–134.
29. [29] Watson, H.G., Keeling, D.M., Laffan, M., Tait, R.C., Makris, M., Guideline on aspects of cancer-related venous thrombosis. Br. J. Haematol. 170 (2015), 640–648.
30. [30] Khorana, A.A., Venous thromboembolism and prognosis in cancer. Thromb. Res. 125 (2010), 490–493.
31. [31] Baron, J.A., Gridley, G., Weiderpass, E., Nyren, O., Linet, M., Venous thromboembolism and cancer. Lancet 351 (1998), 1077–1080.
32. [32] Wilts, I.T., Bleker, S.M., van, E.N., Buller, H.R., Di, N.M., Kamphuisen, P.W., Safety of anticoagulant treatment in cancer patients. Expert Opin. Drug Saf. 14 (2015), 1227–1236.
33. [33] Di Nisio, M., Porreca, E., Candeloro, M., De TM, Russi I., Rutjes, A.W., Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst. Rev., 12, 2016, CD008500.
34. [34] Farge, D., Debourdeau, P., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., Brilhante, D., Falanga, A., Gerotzafias, G.T., Haim, N., Kakkar, A.K., Khorana, A.A., Lecumberri, R., Mandala, M., Marty, M., Monreal, M., Mousa, S.A., Noble, S., Pabinger, I., Prandoni, P., Prins, M.H., Qari, M.H., Streiff, M.B., Syrigos, K., Bounameaux, H., Buller, H.R., International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 11 (2013), 56–70.
35. [35] Zwicker, J.I., Karp, L.R., Carrier, M., A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J. Thromb. Haemost. 14 (2016), 1736–1740.
36. [36] Weinstock, M.J., Uhlmann, E.J., Zwicker, J.I., Intracranial hemorrhage in cancer patients treated with anticoagulation. Thromb. Res. 140:Suppl. 1 (2016), S60–S65.
37. [37] Mandala, M., Falanga, A., Roila, F., Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann. Oncol. 22:Suppl. 6 (2011), vi85–vi92.
38. [38] Lyman, G.H., Khorana, A.A., Kuderer, N.M., Lee, A.Y., Arcelus, J.I., Balaban, E.P., Clarke, J.M., Flowers, C.R., Francis, C.W., Gates, L.E., Kakkar, A.K., Key, N.S., Levine, M.N., Liebman, H.A., Tempero, M.A., Wong, S.L., Prestrud, A.A., Falanga, A., Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31 (2013), 2189–2204.
39. [39] Streiff, M.B., Bockenstedt, P.L., Cataland, S.R., Chesney, C., Eby, C., Fanikos, J., Fogerty, A.E., Gao, S., Goldhaber, S.Z., Hassoun, H., Hendrie, P., Holmstrom, B., Kuderer, N., Lee, J.T., Millenson, M.M., Neff, A.T., Ortel, T.L., Siddiqi, T., Smith, J.L., Yee, G.C., Zakarija, A., McMillian, N., Naganuma, M., Venous thromboembolic disease. J. Natl. Compr. Canc. Netw. 11 (2013), 1402–1429.
40. [40] Khorana, A.A., Carrier, M., Garcia, D.A., Lee, A.Y., Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J. Thromb. Thrombolysis 41 (2016), 81–91.
41. [41] Levine, M.N., Gu, C., Liebman, H.A., Escalante, C.P., Solymoss, S., Deitchman, D., Ramirez, L., Julian, J., A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J. Thromb. Haemost. 10 (2012), 807–814.
42. [42] Lee, A.Y., Levine, M.N., Baker, R.I., Bowden, C., Kakkar, A.K., Prins, M., Rickles, F.R., Julian, J.A., Haley, S., Kovacs, M.J., Gent, M., Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 349 (2003), 146–153.
43. [43] Lee, A.Y., Kamphuisen, P.W., Meyer, G., Bauersachs, R., Janas, M.S., Jarner, M.F., Khorana, A.A., Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 314 (2015), 677–686.
44. [44] Farge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A.A., Pabinger, I., Solymoss, S., Douketis, J., Kakkar, A., International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 17 (2016), e452–e466.
45. [45] Carrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A.A., Lee, A.Y., Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb. Res. 134 (2014), 1214–1219.
46. [46] Gomez-Outes, A., Terleira-Fernandez, A.I., Lecumberri, R., Suarez-Gea, M.L., Vargas-Castrillon E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb. Res. 134 (2014), 774–782.
47. [47] Larsen, T.B., Nielsen, P.B., Skjoth, F., Rasmussen, L.H., Lip, G.Y., Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One, 9, 2014, e114445.
48. [48] Posch, F., Konigsbrugge, O., Zielinski, C., Pabinger, I., Ay, C., Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb. Res. 136 (2015), 582–589.
49. [49] van der Hulle, T., den Exter, P.L., Kooiman, J., van der Hoeven, J.J., Huisman, M.V., Klok, F.A., Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. J. Thromb. Haemost. 12 (2014), 1116–1120.
50. [50] van Es, N., Coppens, M., Schulman, S., Middeldorp, S., Buller, H.R., Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124 (2014), 1968–1975.
51. [51] Vedovati, M.C., Germini, F., Agnelli, G., Becattini, C., Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 147 (2015), 475–483.
52. [52] Bott-Kitslaar, D.M., Saadiq, R.A., McBane, R.D., Loprinzi, C.L., Ashrani, A.A., Ransone, T.R., Wolfgram, A.A., Berentsen, M.M., Wysokinski, W.E., Efficacy and safety of rivaroxaban in patients with venous thromboembolism and active malignancy: a single-center registry. Am. J. Med. 129 (2016), 615–619.
53. [53] Mantha, S., Laube, E., Miao, Y., Sarasohn, D.M., Parameswaran, R., Stefanik, S., Brar, G., Samedy, P., Wills, J., Harnicar, S., Soff, G.A., Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J. Thromb. Thrombolysis 43 (2017), 166–171.
54. [54] Ruff, C.T., Giugliano, R.P., Antman, E.M., Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents. Circulation 134 (2016), 248–261.
55. [55] Salmonson, T., Dogne, J.M., Janssen, H., Garcia, B.J., Blake, P., Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: views from a workshop at the European Medicines Agency (EMA). Eur. Heart J. Cardiovasc. Pharmacother. 3 (2017), 42–47.
56. [56] Arobelidze, S., Haddad, A., Spiro, T., Daw, H., New anticoagulants in cancer patient treatments. Anticancer Drugs 27 (2016), 832–838.
57. [57] Fitzgerald, J.L., Howes, L.G., Drug interactions of direct-acting oral anticoagulants. Drug Saf. 39 (2016), 841–845.
58. [58] Narasimha Krishna, K., Warnock, D.G., Saxena, N., Rizk, D.V., Oral anticoagulants and risk of nephropathy. Drug Saf. 38 (2015), 527–533.
59. [59] Lau, Y.C., Proietti, M., Guiducci, E., Blann, A.D., Lip, G.Y., Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J. Am. Coll. Cardiol. 68 (2016), 1452–1464.
60. [60] Chan, K.E., Giugliano, R.P., Patel, M.R., Abramson, S., Jardine, M., Zhao, S., Perkovic, V., Maddux, F.W., Piccini, J.P., Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J. Am. Coll. Cardiol. 67 (2016), 2888–2899.
61. [61] Piccini, J.P., Stevens, S.R., Chang, Y., Singer, D.E., Lokhnygina, Y., Go, A.S., Patel, M.R., Mahaffey, K.W., Halperin, J.L., Breithardt, G., Hankey, G.J., Hacke, W., Becker, R.C., Nessel, C.C., Fox, K.A., Califf, R.M., Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127 (2013), 224–232.
62. [62] Bautista, J., Bella, A., Chaudhari, A., Pekler, G., Sapra, K.J., Carbajal, R., Baumstein, D., Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure. Clin. Kidney J. 8 (2015), 226–231.
63. [63] Friberg, L., Benson, L., Lip, G.Y., Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur. Heart J. 36 (2015), 297–306.
64. [64] Dahal, K., Kunwar, S., Rijal, J., Schulman, P., Stroke, Lee J., Major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest 149 (2016), 951–959.
65. [65] Li, J., Wang, L., Hu, J., Xu, G., Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: a systematic review and a meta-analysis. Nutr. Metab. Cardiovasc. Dis. 25 (2015), 706–713.
66. [66] Raccah, B.H., Perlman, A., Danenberg, H.D., Pollak, A., Muszkat, M., Matok, I., Major bleeding and hemorrhagic stroke with direct oral anticoagulants in patients with renal failure: systematic review and meta-analysis of randomized trials. Chest 149 (2016), 1516–1524.
67. [67] Nielsen, P.B., Lane, D.A., Rasmussen, L.H., Lip, G.Y., Larsen, T.B., Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin. Res. Cardiol. 104 (2015), 418–429.
68. [68] Chan, K.E., Edelman, E.R., Wenger, J.B., Thadhani, R.I., Maddux, F.W., Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 131 (2015), 972–979.
69. [69] Chai-Adisaksopha, C., Hillis, C., Lim, W., Boonyawat, K., Moffat, K., Crowther, M., Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. J. Thromb. Haemost. 13 (2015), 1790–1798.
70. [70] Stollberger, C., Finsterer, J., Pipe dreams about apixaban for stroke prevention in renal impairment. J. Clin. Pharmacol. 56 (2016), 646–647.
71. [71] Tripodi, A., Primignani, M., Mannucci, P.M., Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. Intern. Emerg. Med. 5 (2010), 7–12.
72. [72] Intagliata, N.M., Northup, P.G., Anticoagulant therapy in patients with cirrhosis. Semin. Thromb. Hemost. 41 (2015), 514–519.
73. [73] Lisman, T., Kamphuisen, P.W., Northup, P.G., Porte, R.J., Established and new-generation antithrombotic drugs in patients with cirrhosis—possibilities and caveats. J. Hepatol. 59 (2013), 358–366.
74. [74] Intagliata, N.M., Henry, Z.H., Maitland, H., Shah, N.L., Argo, C.K., Northup, P.G., Caldwell, S.H., Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig. Dis. Sci. 61 (2016), 1721–1727.
75. [75] Intagliata, N.M., Maitland, H., Northup, P.G., Caldwell, S.H., Treating thrombosis in cirrhosis patients with new oral agents: ready or not. Hepatology 61 (2015), 738–739.
76. [76] Martinez, M., Tandra, A., Vuppalanchi, R., Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology 60 (2014), 425–426.
77. [77] Bates, S.M., Middeldorp, S., Rodger, M., James, A.H., Greer, I., Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J. Thromb. Thrombolysis 41 (2016), 92–128.
78. [78] Cohen, H., Arachchillage, D.R., Middeldorp, S., Beyer-Westendorf, J., bdul-Kadir, R., Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J. Thromb. Haemost. 14 (2016), 1673–1676.
79. [79] Hoeltzenbein, M., Beck, E., Meixner, K., Schaefer, C., Kreutz, R., Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin. Res. Cardiol. 105 (2016), 117–126.
80. [80] Beyer-Westendorf, J., Michalski, F., Tittl, L., Middeldorp, S., Cohen, H., Abdul, K.R., Arachchillage, D.J., Arya, R., Ay, C., Marten, S., Pregnancy outcome in patients exposed to direct oral anticoagulants − and the challenge of event reporting. Thromb. Haemost. 116 (2016), 651–658.
81. [81] vonVajna, E., Alam, R., So, T.Y., Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol. Ther. 5 (2016), 19–41.
82. [82] Monagle, P., Chan, A.K., Goldenberg, N.A., Ichord, R.N., Journeycake, J.M., Nowak-Gottl, U., Vesely, S.K., 9th ed. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 141, 2012, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, e737S–e801S (Chest).
83. [83] Greinacher, A., Clinical practice. Heparin-induced thrombocytopenia. N. Engl. J. Med. 373 (2015), 252–261.
84. [84] Skelley, J.W., Kyle, J.A., Roberts, R.A., Novel oral anticoagulants for heparin-induced thrombocytopenia. J. Thromb. Thrombolysis 42 (2016), 172–178.
85. [85] Dhakal, P., Pathak, R., Giri, S., Murthy, G.S., Bhatt, V.R., New oral anticoagulants for the management of heparin induced thrombocytopenia: a focused literature review. Cardiovasc. Hematol. Agents Med. Chem. 13 (2015), 87–91.
86. [86] Shatzel, J.J., Crapster-Pregont, M., Deloughery, T.G., Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia: a systematic review of 54 reported cases. Thromb. Haemost. 116 (2016), 397–400.
87. [87] Keeling, D., Mackie, I., Moore, G.W., Greer, I.A., Greaves, M., Guidelines on the investigation and management of antiphospholipid syndrome. Br. J. Haematol. 157 (2012), 47–58.
88. [88] Chighizola, C.B., Moia, M., Meroni, P.L., New oral anticoagulants in thrombotic antiphospholipid syndrome. Lupus 23 (2014), 1279–1282.
89. [89] Chighizola, C.B., Raschi, E., Borghi, M.O., Meroni, P.L., Update on the pathogenesis and treatment of the antiphospholipid syndrome. Curr. Opin. Rheumatol. 27 (2015), 476–482.
90. [90] Dufrost, V., Risse, J., Zuily, S., Wahl, D., Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? a systematic review of the literature. Curr. Rheumatol. Rep., 18, 2016, 74.
91. [91] Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R., Mackie, I.J., Clawson, S., Sylvestre, Y., Machin, S.J., Bertolaccini, M.L., Ruiz-Castellano, M., Muirhead, N., Dore, C.J., Khamashta, M., Isenberg, D.A., Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 3 (2016), e426–e436.
92. [92] Pengo, V., Banzato, A., Bison, E., Zoppellaro, G., Padayattil, J.S., Denas, G., Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25 (2016), 301–306.
93. [93] Woller, S.C., Stevens, S.M., Kaplan, D.A., Branch, D.W., Aston, V.T., Wilson, E.L., Gallo, H.M., Johnson, E.G., Rondina, M.T., Lloyd, J.F., Evans, R.S., Elliott, C.G., Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS). Clin. Appl. Thromb. Hemost 22 (2016), 239–247.
94. [94] Ataga, K.I., Stocker, J., The trials and hopes for drug development in sickle cell disease. Br. J. Haematol. 170 (2015), 768–780.
95. [95] Sparkenbaugh, E.M., Chantrathammachart, P., Mickelson, J., van, R.J., Hebbel, R.P., Monroe, D.M., Mackman, N., Key, N.S., Pawlinski, R., Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123 (2014), 1747–1756.
96. [96] Finazzi, G., Ageno, W., Direct oral anticoagulants in rare venous thrombosis. Intern. Emerg. Med. 11 (2016), 167–170.
97. [97] Ageno, W., Beyer-Westendorf, J., Garcia, D.A., Lazo-Langner, A., McBane, R.D., Paciaroni, M., Guidance for the management of venous thrombosis in unusual sites. J. Thromb. Thrombolysis 41 (2016), 129–143.
98. [98] Beyer-Westendorf, J., Schellong, S.M., Gerlach, H., Rabe, E., Weitz, J.I., Jersemann, K., Sahin, K., Bauersachs, R., Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 4 (2017), e105–e113.
99. [99] Plovanich, M., Mostaghimi, A., Novel oral anticoagulants: what dermatologists need to know. J. Am. Acad. Dermatol. 72 (2015), 535–540.
100. [100] Kerk, N., Drabik, A., Luger, T.A., Schneider, S.W., Goerge, T., Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy. Br. J. Dermatol. 168 (2013), 898–899.
101. [101] Winchester, D.S., Drage, L.A., Davis, M.D., Response of livedoid vasculopathy to rivaroxaban. Br. J. Dermatol. 172 (2015), 1148–1150.
102. [102] Weishaupt, C., Strolin, A., Kahle, B., Kreuter, A., Schneider, S.W., Gerss, J., Eveslage, M., Drabik, A., Goerge, T., Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol. 3 (2016), e72–e79.
103. [103] Joseph, P., Pare, G., Wallentin, L., Connolly, S., Yusuf, S., Wang, J., Ezekowitz, M., Eikelboom, J., Siegbahn, A., Reilly, P., Themeles, E., Oldgren, J., Dabigatran etexilate and reduction in serum apolipoprotein B. Heart 102 (2016), 57–62.
104. [104] Prisco, D., Ageno, W., Becattini, C., D'Angelo, A., Davi, G., De, C.R., Dentali, F., Di Minno, G., Falanga, A., Gussoni, G., Masotti, L., Palareti, G., Pignatelli, P., Santi, R.M., Santilli, F., Silingardi, M., Tufano, A., Violi, F., Italian intersociety consensus on DOAC use in internal medicine. Intern. Emerg. Med.(February (13)), 2017, 10.1007/s11739-017-1628-6 (Epubaheadofprint).